Medicare Enrolled
Dr. Philip Mease, MD
Rheumatology · Seattle, WA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mease from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mease?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mease
Dr. Philip Mease is a rheumatology specialist in Seattle, WA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mease performed 19,192 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Mease received a total of $2,208,501 from 70 pharmaceutical and/or device companies across 2455 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mease is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 14% volume in WA
$2,208,501 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗19,192
Medicare services
Top 14% in WA for rheumatology
Not available
Unique patients (not deduplicated)
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
8,000 | $4 | $11 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
7,350 | $11 | $36 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
1,900 | $34 | $68 |
| Denosumab injection (Prolia/Xgeva) | 1,500 | $18 | $46 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
219 | $85 | $213 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
84 | $60 | $335 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
57 | $13 | $43 |
| New patient office visit, complex (60-74 min) | 33 | $167 | $387 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
19 | $123 | $335 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
15 | $65 | $160 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
15 | $146 | $290 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
48.7% high complexity
49.8% medium
1.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,208,501
Total received (2018-2024)
Avg $315,500/year across 7 years
Top 2% in WA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
70
Companies
2,455
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$203,557
2023
$214,969
2022
$290,136
2021
$293,913
2020
$355,081
2019
$462,780
2018
$388,063
Payments by company (2024)
UCB, Inc.
$69,403
ABBVIE INC.
$22,995
PFIZER INC.
$20,193
UCB SA
$19,897
Lilly USA, LLC
$15,012
Novartis Pharmaceuticals Corporation
$12,991
Janssen Biotech, Inc.
$12,774
Amgen Inc.
$9,738
Janssen Scientific Affairs, LLC
$9,484
Takeda Pharmaceuticals U.S.A., Inc.
$4,197
E.R. Squibb & Sons, L.L.C.
$3,349
GlaxoSmithKline, LLC.
$1,469
VERTEX PHARMACEUTICALS INCORPORATED
$1,000
Eli Lilly and Company
$875
Fresenius Kabi USA, LLC
$57
Kiniksa Pharmaceuticals International, plc
$29
Radius Health, Inc.
$28
GENZYME CORPORATION
$27
Organon Llc
$22
AstraZeneca Pharmaceuticals LP
$15
Top 3 companies account for 55.3% of 2024 payments
All-time payments by company (2018-2024) ›
Lilly USA, LLC
$333,080
PFIZER INC.
$242,427
Novartis Pharmaceuticals Corporation
$241,147
Janssen Scientific Affairs, LLC
$186,401
ABBVIE INC.
$169,355
Amgen Inc.
$140,200
Novartis Pharma AG
$128,754
Eli Lilly and Company
$118,392
UCB, Inc.
$116,816
AbbVie Inc.
$88,991
UCB SA
$75,165
E.R. Squibb & Sons, L.L.C.
$70,474
Janssen Biotech, Inc.
$57,702
Celgene Corporation
$48,947
AbbVie, Inc.
$46,408
GlaxoSmithKline, LLC.
$39,997
NOVARTIS PHARMACEUTICALS CORPORATION
$27,341
UCB Biosciences Inc.
$17,746
Janssen Global Services, LLC
$8,912
Regeneron Healthcare Solutions, Inc.
$6,183
Genentech USA, Inc.
$5,696
Genentech, Inc.
$4,978
GENZYME CORPORATION
$4,734
Merck Sharp & Dohme Corporation
$4,236
Takeda Pharmaceuticals U.S.A., Inc.
$4,215
Aurinia Pharma U.S., Inc.
$2,588
Mylan Specialty L.P.
$2,500
Pfizer Inc.
$2,499
CSL Behring
$2,168
Horizon Therapeutics plc
$2,149
Jubilant DraxImage Inc.
$2,000
Gilead Sciences, Inc.
$1,236
VERTEX PHARMACEUTICALS INCORPORATED
$1,000
Vertex Pharmaceuticals Incorporated
$908
Samsung Bioepis Co., Ltd.
$700
Radius Health, Inc.
$264
Horizon Pharma plc
$250
Boehringer Ingelheim International GmbH
$232
Assertio Therapeutics, Inc.
$201
Alexion Pharmaceuticals, Inc.
$128
Mallinckrodt Enterprises LLC
$124
Sobi, Inc
$109
Mallinckrodt LLC
$81
Boehringer Ingelheim Pharma GmbH & Co.KG
$76
Boehringer Ingelheim Pharmaceuticals, Inc.
$74
Kiniksa Pharmaceuticals, Ltd.
$71
Ferring Pharmaceuticals Inc.
$66
Fresenius Kabi USA, LLC
$57
Antares Pharma, Inc.
$57
AstraZeneca Pharmaceuticals LP
$54
Bioventus LLC
$53
Flexion Therapeutics, Inc.
$53
Arcutis Biotherapeutics, Inc.
$50
TerSera Therapeutics LLC
$49
Organon LLC
$48
SOBI, INC
$48
Oxford Immunotec USA Inc
$35
Janssen Research & Development, LLC
$32
Kiniksa Pharmaceuticals International, plc
$29
Mallinckrodt Hospital Products Inc.
$25
Ultragenyx Pharmaceutical Inc.
$24
FIDIA PHARMA USA INC.
$22
Organon Llc
$22
Daiichi Sankyo Inc.
$21
MEDEXUS PHARMA, INC.
$21
Actelion Pharmaceuticals US, Inc.
$19
Mission Pharmacal Company
$16
Hikma Pharmaceuticals USA
$15
West-Ward Pharmaceuticals
$14
SANOFI-AVENTIS U.S. LLC
$13
Top 3 companies account for 37.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AIN457A · AIN457F · AIN457F_COSENTYX_IMMUNOLOGY · AIN_COSENTYX_IMMUNOLOGY · AVSOLA · Actemra · Aquoral · Arcalyst · BENLYSTA · Bimzelx · CELEBREX · COSENTYX · COSENTYX_COSENTYX_DERMATOLOGY · CRH_COSENTYX_IMMUNOLOGY · CUVITRU · CYLTEZO · Cimzia · Crysvita · DUEXIS · Durolane · EUFLEXXA · EVENITY · Enbrel · FORTEO · HADLIMA · HUMIRA · Humira · Hymovis · IDACIO · ILARIS · INFLECTRA · INJECTAFER · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · Mitigare · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OLUMIANT · OPSUMIT MACITENTAN · ORENCIA · OTREXUP · Otezla · Otrexup · Quzyttir · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SECUKINUMAB_COSENTYX_DERMATOLOGY · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SYNVISC-ONE · Sotyktu · Strensiq · TALTZ · TAVNEOS · TREMFYA · TSPOT TB TEST · Tremfya · Tymlos · XELJANZ · Zilretta
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Rheumatologists in nearby ZIP areas
94
County median income
$122,148
Nearest hospital to ZIP centroid (approximate)
HARBORVIEW MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mease is a mixed practice specialist, with above-average Medicare volume (top 14% in WA), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mease experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Mease performed 8,000 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Mease receive payments from pharmaceutical companies?
Yes. Dr. Mease received a total of $2,208,501 from 70 companies across 2,455 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mease's costs compare to other rheumatologists in Seattle?
Dr. Mease's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mease) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Seattle
Browse rheumatologists in Seattle ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in WA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in WA
Which WA rheumatologists receive the most from drug and device companies.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology